 |
Multiple growth factor solutions were introduced to the US market in
the 1980’s and since then the body of clinical evidence has grown.
In January 2001, Cytomedix obtained exclusive ownership of
technology, assets and intellectual property rights associated with
the use of autologous multiple growth factors. In recent years,
significant events have fueled the commercial opportunities for
Cytomedix owned technology and the AutoloGel System. In 2006,
Cytomedix published a randomized clinical trial demonstrating
significant improved wound outcomes. In 2007, FDA cleared the
AutoloGel System for chronic wounds. In addition, Cytomedix has
licensed the technology for use in orthopedic and surgical
applications. Today, Cytomedix is involved in the development of
various peptides and autologous technologies, as advanced biological
solutions to control inflammation.
 Technology
|
|
